The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1663-1666

  Micke, Oliver ^a   Bruns, Frank ^a   Schäfer, Ulrich ^a   Prott, Franz Josef ^a   Willich, Normann ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer; Radiotherapy; SCC antigen; Uterine cervix

Indexed keywords

CISPLATIN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 21244479402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Micke O, Bruns F, Schafer U, Horst E, Buntzel J and Willich N: The clinical value of squamous cell carcinoma antigen in patients irradiated for locally advanced cancer of the head and neck. Anticancer Res 23: 907-911, 2003.
2. Kato H, Miyauchi F, Morioka H, Fujino T and Torigoe T: Tumor antigen of cervical squamous cell carcinoma. Correlation of circulating levels with disease progress. Cancer 43: 585-590, 1979.
3. Kato H, Morioka H, Aramaki S, Tanai S and Torigoe T: Tumour antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer 54: 1544-1546, 1984.
4. Torre GC: SCC antigen in malignant and nonmalignant squamous lesions. Tumor Biol 19: 517-526, 1998.
5. Berclaz G, Gerber E, Beer K, Aebi S, Greiner R, Dreher E and Buser K: Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochemotherapy. Int J Oncol 20: 1313-1318, 2002.
6. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B and Cavallin-Stahl E: A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol 42: 546-556, 2003.
7. Meier W, Stieber P, Hasholzner U, Baumgartner L and Fateh-Moghadam A: Prognostic significance of serum squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma. Anticancer Res 17: 2959-2962, 1997.
8. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R and Willich N: The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 20: 5113-5115, 2000.
9. Duk JM, De Bruijn HWA, Groenier KH, Hollema H, Ten Hoor KA, Krans M and Aalders E: Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 39: 186-194, 1990.
10. Lozza L, Merola M, Fontanelli R, Stefanou B, Serigni E, Bombadieri E and De Palo G: Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Anticancer Res 17: 525-529, 1997.
11. Abe A, Nakano T, Morita S and Oka K: Clinical evaluation of serum and immunohistochemical expression of SCC and CA 19-9 in radiation therapy for cervical cancer. Anticancer Res 19: 829-836, 1999.
12. Gaarenstroom KN, Bonferer JMG, Korse CM, Kenter GG and Kenemans P: Value of Cyffra 21-1, TPA and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res 17: 2955-2958, 1997.
13. De Bruijn HWA, Duk JM, van der Zee AGJ, Pras E, Willemse PHB, Boonstra H, Hollema H, Mourits MJE, de Vries EGE and Aalders E: The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumor Biol 19: 505-516, 1998.
14. Morley GW, Hopkins MP, Lindenauer SM and Roberts JA: Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 74: 934-943, 1989.
15. Hille A, Weiss E and Hess CF: Therapeutic outcome and prognostic factors in the radiotherapy of recurrences of cervical carcinoma following surgery. Strahlenther Onkol 179: 742-747, 2003.
16. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, Tseng CJ, Chang TC and Tang SG: The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 41: 823-830, 1998.
17. Wagner RK, Atzinger A and Breit A: The monitoring of gynecological radiotherapy using serial tumor marker determination. Strahlenther Onkol 166: 446-452, 1990.
18. Yazigi R, Munoz AK, Richardson B and Risser R: Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer. Gynecol Oncol 41: 135-138, 1991.
19. Nehmzow M, Deinas M, Köhler G and Breitsprecher R: The clinical value of serum CEA and serum SCC in advanced squamous cell carcinoma of the cervix treated with chemoradiation. Anticancer Res 19: 5691, 1999.
20. Hansgen G, Kuhnt T, Pigorsch S, Strauss H and Dunst J: Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study. Strahlenther Onkol 178: 71-77, 2002.